Title of article :
The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer
Author/Authors :
Hasbek, Zekiye Cumhuriyet University Faculty of Medicine - Department of Nuclear Medicine - Sivas, Turkey , Turgut, Bülent Cumhuriyet University Faculty of Medicine - Department of Nuclear Medicine - Sivas, Turkey , Doğan, Ömer Tamer Cumhuriyet University Faculty of Medicine - Department of Chest Diseases - Sivas, Turkey , Berk, Serdar Cumhuriyet University Faculty of Medicine - Department of Chest Diseases - Sivas, Turkey , Sarı, İsmail Cumhuriyet University Faculty of Medicine - Department of Biochemistry - Sivas, Turkey , Siliğ, Yavuz Cumhuriyet University Faculty of Medicine - Department of Biochemistry - Sivas, Turkey , Yücel, Birsen Cumhuriyet University Faculty of Medicine - Department of Radiation Oncology - Sivas, Turkey , Şeker, Mehmet Metin Turgut Özal University Faculty of Medicine - Department of Medical Oncology - Ankara, Turkey
Abstract :
Mutations in the p53 gene are the most commonly observed genetic abnormalities in malignancies. The purpose of this study was to assess the diagnostic value of serum anti-p53 antibody (Ab) along with the correlation between serum anti-p53 Ab level and quantitative positron emission tomography (PET) parameters such as maximum standardized uptake value (SUVmax), SUVave, metabolic tumor volume, total lesion glycolysis (TLG) and tumor size. Methods: Serum anti-p53 Ab level was studied in three groups. Patients who underwent 18F-fluorodeoxyglucose (FDG) PET/computed tomography (CT) imaging for staging of previously diagnosed lung cancer constituted the first group, while patients who underwent 18F-FDG PET/CT imaging for evaluation of suspicious pulmonary nodules detected on thorax CT and did not show pathologic FDG accumulation (NAPN=pulmonary nodule with non avid-FDG) were enrolled in the second group. The third group consisted of healthy volunteers.Results: Twenty-eight patients with lung cancer (median age: 62.5, range: 39-77years), 28 patients with NAPN (median age: 65, range: 33-79 years), and 24 healthy volunteers (median age: 62, range: 44-74 years) were enrolled in the study. The serum anti-p53 Ab level was low in healthy volunteers while it was higher in both lung cancer patients and NAPN patients (p<0.05). When serum anti-p53 Ab level and PET parameters were evaluated, there was no significant correlation between serum anti-p53 Ab level and SUVmax, SUVave, TLG, tumor volume and tumor size of patients with lung cancer (p>0.05). Besides, there was no significant difference between serum anti-p53 Ab level and lesion size of NAPN patients (p>0.05). Conclusion: It was determined that serum anti-p53 Ab levels are not significantly correlated with PET parameters, and that serum anti-p53 Ab levels increase in any benign or malignant lung parenchyma pathology as compared to healthy volunteers. These results indicate that this Ab cannot be used as a predictor of malignancy in a lung lesion.
Keywords :
fluorodeoxyglucose , positron emission tomography/computed tomography , lung cancer , Anti-p53 antibody
Journal title :
Molecular Imaging and Radionuclide Therapy